On the Brink of a New Frontier: BioNTech’s Bold Shift from Covid Vaccines to Cancer Treatments
BioNTech is shifting its focus from Covid-19 vaccines to mRNA-based cancer treatments, aiming for market approval by 2026. Despite a drop in annual revenue, BioNTech is committed to advancing research,…